Some independent practices utilize clinical pathways to mange complex regimens, but lack of education and cost concerns may limit practices' use of clinical pathways, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Some independent practices utilize clinical pathways to mange complex regimens, but lack of education and cost concerns may limit practices' use of clinical pathways, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Transcript:
What are the challenges and benefits of using clinical pathways for an independent practice?
I think independent practices have a great opportunity to use those clinical pathways in a way to create efficiencies within the practice in order to better manage complex chemotherapy regimens, as well as to manage much of the complex symptoms associated with with cancer patients actively on therapy. I think a lot of practices have not implemented pathways yet, partly because of just lack of education or exposure. I think some practices feel that they have their own methodologies in place just by doing it on their own. Then sometimes there's the cost of a pathway system that comes into play. As far as Quality Cancer Care Alliance (QCCA) goes, as a group and through group purchasing, we've been able to create what I think are financially advantageous opportunities to be able to run clinical pathways within independent practice groups.
How does participating in Quality Cancer Care Alliance foster productive use of clinical pathways?
Clinical pathways is a core element, in my opinion, on being able to provide value-based care. That's one of the major objectives of QCCA as a network of strong independent practices in order to optimize value-based delivery of care. QCCA feels strongly that the implementation of clinical pathways and symptom management pathways is part of the stuff that we need in order to achieve value-based delivery of care.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More